Clinical Trials Logo

Clinical Trial Summary

This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06155422
Study type Observational
Source Tongji Hospital
Contact Ding Ma
Phone 86-027-8362681
Email dma@tjh.tjmu.edu.cn
Status Not yet recruiting
Phase
Start date November 30, 2023
Completion date November 30, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04623333 - A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer Phase 2
Active, not recruiting NCT04680988 - A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer Phase 2
Completed NCT04868708 - A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer Phase 2